Stockscreener 앱 받기
33.71
0.13%
-0.044
시장 영업 전:
32.20
-1.506
-4.47%
Scholar Rock Holding Corp 주식(SRRK)의 최신 뉴스
Scholar Rock (NASDAQ:SRRK) Insider Sells $102,836.51 in Stock - MarketBeat
SRRK: Piper Sandler Maintains Rating but Lowers Price Target | S - GuruFocus
Another Catalent Indiana delay: Scholar Rock gets CRL for apitegromab - BioWorld MedTech
SRRK: Barclays Maintains 'Overweight' Rating, Lowers Price Targe - GuruFocus
Piper Sandler lowers Scholar Rock stock price target on FDA rejection - Investing.com UK
Scholar Rock (NASDAQ:SRRK) Price Target Lowered to $44.00 at Barclays - MarketBeat
Scholar Rock stock price target lowered to $44 at H.C. Wainwright on FDA delay - Investing.com
Leerink Partners lowers Scholar Rock stock price target to $48 on CRL delay - Investing.com
Voya Investment Management LLC Cuts Stock Holdings in Scholar Rock Holding Corporation $SRRK - MarketBeat
FDA issues complete response letter for Scholar Rock’s SMA drug By Investing.com - Investing.com South Africa
Scholar Rock (NASDAQ:SRRK) Shares Gap Down Following Analyst Downgrade - MarketBeat
SRRK: Analyst Maintains Rating but Lowers Price Target to $44 | - GuruFocus
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection - Benzinga
Scholar Rock (NASDAQ:SRRK) Price Target Cut to $44.00 by Analysts at HC Wainwright - MarketBeat
Another Catalent delay: Scholar Rock gets CRL for apitegromab - BioWorld MedTech
Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says - MarketScreener
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues - Stocktwits
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug - inkl
US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall - Reuters
FDA Rejection Sends Scholar Rock (SRRK) Shares Plummeting - GuruFocus
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Scholar Rock Faces FDA Setback on SMA Drug Due to Manufacturing Site Issues - MarketScreener
Scholar Rock stock falls after FDA issues response letter for SMA drug - Investing.com Nigeria
FDA issues complete response letter for Scholar Rock’s SMA drug - Investing.com
US FDA declines to approve Scholar Rock's muscle weakness drug - MarketScreener
FDA Delays First-Ever Muscle-Targeted SMA Treatment: Scholar Rock's Apitegromab Hits Manufacturing Hurdle - Stock Titan
Scholar Rock SMA drug rejected by FDA over manufacturing concerns - Yahoo Finance
Scholar Rock (NASDAQ:SRRK) Now Covered by Barclays - MarketBeat
Scholar Rock (NASDAQ:SRRK) Shares Up 9%What's Next? - MarketBeat
Should you wait for a breakout in Scholar Rock Holding CorporationPortfolio Performance Summary & Expert Verified Movement Alerts - newser.com
Is Scholar Rock Holding Corporation a candidate for recovery playEarnings Risk Summary & High Accuracy Buy Signal Tips - newser.com
Scholar Rock (NASDAQ:SRRK) Coverage Initiated at Barclays - MarketBeat
Can machine learning forecast Scholar Rock Holding Corporation recoveryQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - newser.com
Insider Selling: Scholar Rock (NASDAQ:SRRK) Director Sells 1,006 Shares of Stock - MarketBeat
Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells 3,178 Shares of Stock - MarketBeat
Leerink Partnrs Forecasts Scholar Rock Q3 Earnings - MarketBeat
Full technical analysis of Scholar Rock Holding Corporation stockTrade Risk Assessment & Free Daily Entry Point Trade Alerts - newser.com
Scholar Rock (NASDAQ:SRRK) Trading Down 5%Here's Why - MarketBeat
What to expect from Scholar Rock Holding Corporation in the next 30 daysJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Intech Investment Management LLC Purchases 21,483 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
History Review: Is Scholar Rock Holding Corporation stock a falling knife or bargain buy2025 Short Interest & Real-Time Price Movement Reports - khodrobank.com
Voya Investment Management LLC Cuts Position in Scholar Rock Holding Corporation $SRRK - Defense World
Scholar Rock (NASDAQ:SRRK) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Published on: 2025-09-19 23:11:54 - newser.com
Will Scholar Rock Holding Corporation benefit from macro trendsQuarterly Market Review & Community Supported Trade Ideas - newser.com
Scholar Rock shares close 6% higher after Leerink initiates at outperform - MSN
What machine learning models say about Scholar Rock Holding Corporation2025 Key Highlights & Detailed Earnings Play Alerts - newser.com
Long term hold vs stop loss in Scholar Rock Holding CorporationWall Street Watch & High Accuracy Swing Entry Alerts - newser.com
How moving averages guide Scholar Rock Holding Corporation tradingJuly 2025 Trends & Fast Gaining Stock Strategy Reports - newser.com
Ideas Watch: Can Scholar Rock Holding Corporation disrupt its industry2025 Historical Comparison & Daily Volume Surge Trade Alerts - خودرو بانک
Chart based exit strategy for Scholar Rock Holding Corporation2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
Momentum Shift: Is Scholar Rock Holding Corporation stock a good pick for beginners2025 Price Targets & Long-Term Growth Portfolio Plans - خودرو بانک
Scholar Rock (NASDAQ:SRRK) Now Covered by Leerink Partners - MarketBeat
Developing predictive dashboards with Scholar Rock Holding Corporation dataJuly 2025 Patterns & Fast Entry High Yield Tips - newser.com
Historical volatility pattern of Scholar Rock Holding Corporation visualizedJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Scholar Rock (NASDAQ:SRRK) Research Coverage Started at Barclays - Defense World
1.30%
2.51%
자본화:
|
볼륨(24시간):